期刊
CANCER DISCOVERY
卷 6, 期 10, 页码 1084-1086出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-16-0910
关键词
-
类别
资金
- LUNGevity Foundation Career Development Award
- Damon Runyon Clinical Investigator Award
- V Foundation Scholar-in-Training Award
- AACR-Genentech Career Development Award
- National Institutes of Health (NIH) and National Cancer Institute (NCI) [R01-CA121210, P01-CA129243]
In the setting of recent exciting clinical results and numerous ongoing trials, Gainor and colleagues explored mechanisms of acquired resistance to first-and second-generation ALK inhibitors in ALK - rearranged non-small cell lung cancer and found that an increased frequency and distinct spectrums of resistance mutations emerged with the more potent second-generation inhibitors. Their findings have important and immediate clinical implications as the resistance mutations detected impart differential sensitivities to available ALK inhibitors, thereby highlighting the need for sequential biopsies with molecular testing to determine the most effective treatment strategy upon disease progression. (C) 2016 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据